Effects of administration of fostamatinib on blood concentrations of Pioglitazone in healthy subjects

Study identifier:D4300C00014

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects when Administered Alone and in Combination with Fostamatinib 100 mg Twice Daily

Medical condition

Rheumatoid Arthritis, Healthy Volunteers, pharmacokinetics

Phase

Phase 1

Healthy volunteers

Yes

Study drug

fostamatinib, pioglitazone

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Mar 2011

Primary Completion Date: 01 May 2011

Study Completion Date: 01 May 2011

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Overland Park, Kansas, United States

Arms	Assigned Interventions
Experimental: pioglitazone	Drug: fostamatinib oral tablets, 100mg (2 X 50mg) twice daily for 8 days Drug: pioglitazone oral tablets, 30mg single dose per period
Experimental: pioglitazone and fostamatinib	Drug: pioglitazone oral tablets, 30mg single dose per period

"There is no result for the study"

Documents available

D4300C00014 Clinical Report Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

Quintiles, Overland Park, volunteer recruitment

(913) 894-5533

Investigators

Principal Investigator

Mark Layton

AstraZeneca